These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33126939)

  • 1. Introduction and scaling up of new drugs for drug-resistant TB: experiences from the Americas.
    Bernal O; Lopez R; Montoro E; Avedillo P; Westby K; Ghidinelli M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1058-1062. PubMed ID: 33126939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
    Cox V; Brigden G; Crespo RH; Lessem E; Lynch S; Rich ML; Waning B; Furin J
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):407-412. PubMed ID: 29562988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
    Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
    Seaworth BJ; Griffith DE
    Microbiol Spectr; 2017 Mar; 5(2):. PubMed ID: 28361737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthened capacity of India´s bedaquiline Conditional Access Programme for introducing new drugs and regimens.
    Sachdeva KS; Arora N; Solanki R; Singla R; Sarin R; Bhatnagar A; Khanna A; Atahavale A; Shridhar R; Barua SR; Parmar M; Farooq SI; Ramachandran R; Alavadi U; Swamickan R; Tonsing J; Patel Y; Singla N
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1067-1072. PubMed ID: 33126941
    [No Abstract]   [Full Text] [Related]  

  • 8. Overcoming barriers to the access and uptake of newer drugs for multidrug-resistant TB.
    Zabsonre I; Thi SS; Cox V
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1054-1057. PubMed ID: 33126938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis.
    Shah I; Poojari V; Meshram H
    Indian J Pediatr; 2020 Oct; 87(10):833-839. PubMed ID: 32103425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
    Guglielmetti L; Hewison C; Avaliani Z; Hughes J; Kiria N; Lomtadze N; Ndjeka N; Setkina S; Shabangu A; Sikhondze W; Skrahina A; Veziris N; Furin J
    Int J Tuberc Lung Dis; 2017 Feb; 21(2):167-174. PubMed ID: 28234080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India.
    Muniyandi M; Ramachandran R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey.
    Wang G; Jiang G; Jing W; Zong Z; Yu X; Chen S; Li W; Huang H
    J Infect; 2021 Mar; 82(3):371-377. PubMed ID: 33556430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings.
    Sloan DJ; Lewis JM
    Trans R Soc Trop Med Hyg; 2016 Mar; 110(3):163-72. PubMed ID: 26884496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini.
    Vambe D; Kay AW; Furin J; Howard AA; Dlamini T; Dlamini N; Shabangu A; Hassen F; Masuku S; Maha O; Wawa C; Mafukidze A; Altaye K; Sikhondze W; Gwitima T; Keus K; Simelane T; Kerschberger B
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1095-1102. PubMed ID: 33126945
    [No Abstract]   [Full Text] [Related]  

  • 19. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bedaquiline Donation Program: progress and lessons learned after 4 years of implementation.
    Rutta E; Kambili C; Mukadi Y
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1039-1045. PubMed ID: 33126936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.